Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Safety and Effectiveness of Oral Semaglutide for Patients with High Blood Sugar After Kidney Transplantation

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the safety and effectiveness of a medication called oral semaglutide, which is marketed under the name Rybelsus. The study is specifically for patients who experience high blood sugar levels, known as hyperglycemia, after undergoing a kidney transplant. The trial will compare the effects of Rybelsus with a placebo, both used alongside the usual care that patients receive.

The main goal of the study is to determine if Rybelsus is as effective as the placebo in managing blood sugar levels in these patients. Participants in the study will take either Rybelsus or a placebo in the form of tablets. The study will last for a period of 14 days, during which the participants' blood sugar levels will be closely monitored. This will help researchers understand how well the medication works in controlling blood sugar levels in patients who have had a kidney transplant.

Throughout the study, various health indicators will be observed, such as body weight, blood pressure, and kidney function. The study will also track any side effects or adverse events that participants may experience. The trial is expected to continue until September 2026, providing valuable insights into the management of high blood sugar in patients after kidney transplantation.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the clinical trial, you will have an initial visit with the study team. During this visit, your eligibility will be confirmed, and you will receive detailed information about the trial procedures.

    You will be asked to provide written informed consent, which means you agree to participate in the study after understanding all the details.

  2. Step 2

    Baseline assessments

    Baseline assessments will be conducted to gather information about your current health status. This includes measuring your blood glucose levels, body weight, blood pressure, and other relevant health indicators.

    These assessments help establish a starting point for evaluating the effects of the treatment during the trial.

  3. Step 3

    Medication administration

    You will be randomly assigned to receive either the active medication, Rybelsus (containing semaglutide), or a placebo. The medication is taken orally in tablet form.

    The dosage of Rybelsus will start at 3 mg and may be increased to 7 mg and then to 14 mg, depending on your response and tolerance. The frequency and duration of administration will be explained by the study team.

  4. Step 4

    Regular follow-up visits

    You will have regular follow-up visits with the study team. These visits are important for monitoring your health and the effects of the medication.

    During these visits, various health parameters will be measured, including blood glucose levels, body weight, and blood pressure. You will also be asked about any side effects or changes in your health.

  5. Step 5

    Continuous glucose monitoring

    Throughout the trial, your blood glucose levels will be continuously monitored using a device called a continuous glucose monitor (CGM). This device tracks your glucose levels throughout the day and night.

    The data collected from the CGM will help assess how well the medication is managing your blood glucose levels.

  6. Step 6

    Final assessment

    At the end of the trial, a final assessment will be conducted to evaluate the overall effects of the treatment on your health.

    This assessment will include a comprehensive review of your health parameters, including blood glucose levels, body weight, and any side effects experienced during the trial.

Who can join the trial?

5 criteria

  • Provide written informed consent before any trial-related procedures are performed. This means you agree to participate after being informed about the study.
  • Be a male or female aged between 18 and 80 years.
  • Have a diagnosis of post-transplant hyperglycaemia 10 to 15 days after kidney transplantation. This means your blood sugar levels are high after receiving a kidney transplant. Specifically, your fasting plasma glucose should be at least 7.0 mmol/L, or your plasma glucose should be at least 11.1 mmol/L after a glucose tolerance test.
  • Have an eGFR (estimated glomerular filtration rate) greater than 15 ml/min/1.73 m² 10 to 15 days after kidney transplantation. This is a measure of how well your kidneys are working.
  • Be willing and able to follow the trial protocol. This means you agree to follow the study's rules and procedures.

Who cannot join the trial?

8 criteria

  • Patients who have not had a kidney transplant cannot participate.
  • Patients who do not have high blood sugar levels after a kidney transplant cannot participate.
  • Patients who are under 18 years old cannot participate.
  • Patients who are over 75 years old cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have a history of severe allergic reactions to the study medication cannot participate.
  • Patients who are currently participating in another clinical trial cannot participate.
  • Patients with any other medical condition that the study doctors think might make it unsafe for them to participate cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Oral Semaglutide (Rybelsus) is a medication used in this clinical trial to help manage blood sugar levels in patients who have high blood sugar after receiving a kidney transplant. It is taken by mouth and works by helping the body produce more insulin, which helps lower blood sugar levels. The goal of using this medication in the trial is to see if it can effectively control blood sugar without causing harm, compared to a placebo, when added to the usual care that patients receive.

What is already known about the treatment

Rybelsus – Rybelsus is an oral medication taken by mouth, designed to help manage blood sugar levels in patients who have high blood sugar after receiving a kidney transplant. It is currently being studied in clinical trials to determine its safety and effectiveness in this specific group of patients. The main use of Rybelsus is to control blood sugar levels, and it works by mimicking a natural hormone in the body that helps regulate insulin and blood sugar. It belongs to a class of drugs known as GLP-1 receptor agonists, which help the body use insulin more effectively.

Investigated diseases

Hyperglycemia after renal transplantation – This condition occurs when there is an elevated level of glucose in the blood following a kidney transplant. It can develop due to the use of immunosuppressive medications, which are necessary to prevent organ rejection but can affect glucose metabolism. The progression involves fluctuations in blood sugar levels, which may lead to periods of high glucose. Over time, persistent hyperglycemia can affect the function of the transplanted kidney and other organs. Monitoring and managing blood glucose levels are crucial to prevent complications. The condition requires careful observation to maintain glucose within a target range.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-504159-29-01Estimated enrolment104 patientsSponsorRegion Hovedstaden

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.